Advanced search
Publication Cover
Infection and Drug Resistance Volume 12, 2019 - Issue
Submit an article Journal homepage
129
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Efficacy and safety of cycloserine-containing regimens in the treatment of multidrug-resistant tuberculosis: a nationwide retrospective cohort study in China

Jing Wang1 Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, P.R. China, [email protected]
,
Yu Pang2 National Clinical Laboratory on Tuberculosis, Beijing Chest Hospital affiliated to Capital Medical University, Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, P.R. China
,
Wei Jing1 Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, P.R. China, [email protected]
,
Wei Chen1 Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, P.R. China, [email protected]
,
Ru Guo1 Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, P.R. China, [email protected]
,
Xiqin Han1 Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, P.R. China, [email protected]
,
Limin Wu3 Tuberculosis Prevention Institute, Hangzhou Center for Disease Control and Prevention, Zhejiang 310021, P.R. China
,
Guangxu Yang4 Tuberculosis Prevention Institute, Changchun Infectious Disease Hospital, Jilin 130123, P.R. China
,
Kunyun Yang5 Department of Tuberculosis Resistance, Hunan Chest Hospital, Hunan 410013, P.R. China
,
Cong Chen6 Multidrug Resistant Tuberculosis Project Office, Wuhan Pulmonary Hospital, Hubei 430030, P.R. China
,
Lin Jiang7 Department of Internal Medicine, The Fifth People’s Hospital of Ganzhou, Jiangxi 341000, P.R. China
,
Chunkui Cai8 Department of Drug-Resistant Tuberculosis, Dalian Tuberculosis Hospital, Liaoning, 116033, P.R. China
,
Zhi Dou9 Department of Tuberculosis, Qiqihar Tuberculosis Prevention and Control Institute, Heilongjiang 161006, P.R. China
,
Lijuan Diao10 Department of Tuberculosis, Nanyang Tuberculosis Control Institute, Henan 473000, P.R. China
,
Hongqiu Pan11 Department of Tuberculosis, The Third People’s Hospital of Zhenjiang, Jiangsu 212000, P.R. China
,
Jianyun Wang12 Department of Infection, Lanzhou Pulmonary Hospital, Gansu 730046, P.R. China
,
Feifei Du13 Department of Respiratory, The Fourth People’s Hospital of Ningxia Hui Autonomous Region, Ningxia 750021, P.R. China
,
Tao Xu14 Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & School of Basic Medicine, Peking Union Medical College, Beijing 100005, P.R. China
,
Lixia Wang15 National Center for Tuberculosis Control and Prevention, Chinese Center For Disease Control and Prevention, Beijing 102206, P.R. China
,
Renzhong Li16 Department of Tuberculosis Resistance Prevention and Control, Chinese Center for Disease Control and Prevention, Beijing 102206, P.R. China, [email protected]Correspondence[email protected]
&
Naihui Chu1 Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, P.R. China, [email protected]Correspondence[email protected]
 show all
Pages 763-770 | Published online: 03 Apr 2019

References

  • GandhiNRNunnPDhedaKMultidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosisLancet201037597281830184320488523
  • MarksSMFloodJSeaworthBTreatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007Emerg Infect Dis201420581282124751166
  • World Health OrganizationGlobal Tuberculosis Report 2017GenevaWorld Health Organization2017
  • YuM-CChiangC-YLeeJ-JTreatment outcomes of multidrug-resistant tuberculosis in Taiwan: tackling loss to follow-upClin Infect Dis201867220221029394358
  • World Health OrganizationGlobal Tuberculosis Report 2014GenevaWorld Health Organization
  • EpsteinIGNairKGBoydLJCycloserine, a new antibiotic, in the treatment of human pulmonary tuberculosis: a preliminary reportAntibiotic Med Clin Ther1955128093
  • HwangTJWaresDFJafarovAJakubowiakWNunnPKeshavjeeSSafety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysisInt J Tuberc Lung Dis201317101257126623735593
  • WHO guidelines approved by the guidelines review CommitteeWho Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 UpdateGenevaWorld Health Organization2016
  • LambertMPNeuhausFCMechanism of D-cycloserine action: alanine racemase from Escherichia coli WJ Bacteriol197211039789874555420
  • YewWWWongCFWongPCLeeJChauCHAdverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacinClin Infect Dis19931722882898399888
  • YeeDValiquetteCPelletierMParisienIRocherIMenziesDIncidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosisAm J Respir Crit Care Med2003167111472147712569078
  • ZhaoYXuSWangLNational survey of drug-resistant tuberculosis in ChinaN Engl J Med2012366232161217022670902
  • XuCPangYLiRClinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in ChinaJ Infect201876434835329374587
  • LasersonKFThorpeLELeimaneVSpeaking the same language: treatment outcome definitions for multidrug-resistant tuberculosisInt J Tuberc Lung Dis20059664064515971391
  • WangQPangYJingWClofazimine for treatment of extensively drug-resistant pulmonary tuberculosis in ChinaAntimicrob Agents Chemother2018624e021491729378718
  • Division of AIDS, National Institute of allergy and infectious diseases National Institutes of health, US department of health and Human servicesDivision of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events: corrected version 2.12017 Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcor-rectedv21.pdfAccessed March 20, 2019
  • BrennanPJCrickDCThe cell-wall core of Mycobacterium tuberculosis in the context of drug discoveryCurr Top Med Chem20077547548817346193
  • HorneDTomaszATolerant response of Streptococcus sanguis to beta-lactams and other cell wall inhibitorsAntimicrob Agents Chemother1977115888896879739
  • AungKJMvan DeunADeclercqESuccessful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patientsInt J Tuberc Lung Dis201418101180118725216831
  • RajagopalanSTuberculosis and aging: a global health problemClin Infect Dis20013371034103911528577
  • MartinLRWilliamsSLHaskardKBDimatteoMRThe challenge of patient adherenceTher Clin Risk Manag20051318919918360559
  • BakerMAHarriesADJeonCYThe impact of diabetes on tuberculosis treatment outcomes: a systematic reviewBMC Med201198121722362
  • WorknehMHBjuneGAYimerSAPrevalence and associated factors of tuberculosis and diabetes mellitus comorbidity: a systematic reviewPLoS One2017124e017592528430796
  • ZhuHGuoS-CLiuZ-QTherapeutic drug monitoring of cycloserine and linezolid during anti-tuberculosis treatment in Beijing, ChinaInt J Tuberc Lung Dis201822893193629991404
  • YuXZengXShiWValidation of cycloserine efficacy in treatment of multidrug-resistant and extensively drug-resistant tuberculosis in Beijing, ChinaAntimicrob Agents Chemother2018623 e01824–17pii

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.